Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity

Autor: Frederick L. Locke, Tanya Siddiqi, Caron Alyce Jacobson, Armin Ghobadi, Sairah Ahmed, David Bernard Miklos, Miguel-Angel Perales, Javier Munoz, Brent Logan, Zhen-Huan Hu, Harry H. Miao, Kanwarjit Singh, Jina Shah, Hairong Xu, Marcelo C. Pasquini

Publikováno v: Journal of Clinical Oncology. 40:7571-7571

7571 Background: In clinical trials of CAR T-cell therapies and real-world studies published to date, there is a paucity of data on outcomes by race and ethnicity. Here, we examined outcomes by race and ethnicity among LBCL pts who received axi-cel i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::05ddb72928ed5ace15a5a9ed1e320589
https://doi.org/10.1200/jco.2022.40.16_suppl.7571

A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC

Autor: Johanna C. Bendell, Harry H. Miao, Aaron Moss, Richard D. Kim, Neeraj Gupta, James M. Cleary, Aparna Raj Parikh, Shining Wang, Alexis D. Leal, Joanna Pye, David P. Ryan, Brittany Bahamon

Publikováno v: Journal of Clinical Oncology. 39:3050-3050

3050 Background: TAK-164 is a second-generation ADC comprising a human IgG1 monoclonal antibody targeting GCC conjugated to a DNA-damaging alkylating agent by a peptide linker. TAK-164 demonstrated cytotoxic and antitumor activity in GCC-expressing c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::59822456a6048047c0e5328231e718db
https://doi.org/10.1200/jco.2021.39.15_suppl.3050

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.

Autor: Locke FL; Moffitt Cancer Center, Tampa, FL., Siddiqi T; City of Hope National Medical Center, Duarte, CA., Jacobson CA; Dana-Farber Cancer Institute, Boston, MA., Ghobadi A; Division of Oncology, Washington University School of Medicine, St Louis, MO., Ahmed S; Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Miklos DB; Blood and Marrow Transplantation and Cellular Therapy Division, Stanford University School of Medicine, Stanford, CA., Perales MA; Memorial Sloan Kettering Cancer Center, New York, NY., Munoz J; Department of Hematology, Mayo Clinic Arizona, Phoenix, AZ., Fingrut WB; Memorial Sloan Kettering Cancer Center, New York, NY., Pennisi M; Hematology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Gauthier J; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA., Shadman M; Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA., Gowda L; Yale School of Medicine, Yale Cancer Center, New Haven, CT., Mirza AS; Moffitt Cancer Center, Tampa, FL.; Yale School of Medicine, Yale Cancer Center, New Haven, CT., Abid MB; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI., Hong S; Department of Medicine, Duke University School of Medicine, Durham, NC., Majhail NS; Sarah Cannon Transplant and Cellular Therapy Program, Sarah Cannon Cancer Institute, Nashville, TN., Kharfan-Dabaja MA; Departments of Hematology and Oncology (Medical), Mayo Clinic Florida, Jacksonville, FL., Khurana A; Division of Hematology, Mayo Clinic, Rochester, MN., Badar T; Departments of Hematology and Oncology (Medical), Mayo Clinic Florida, Jacksonville, FL., Lin Y; Division of Hematology, Mayo Clinic, Rochester, MN., Bennani NN; Division of Hematology, Mayo Clinic, Rochester, MN., Herr MM; Roswell Park Comprehensive Cancer Center, Buffalo, NY., Hu ZH; Kite, a Gilead company, Santa Monica, CA., Wang HL; Kite, a Gilead company, Santa Monica, CA., Baer A; Kite, a Gilead company, Santa Monica, CA., Baro E; Kite, a Gilead company, Santa Monica, CA., Miao H; Kite, a Gilead company, Santa Monica, CA., Spooner C; Kite, a Gilead company, Santa Monica, CA., Xu H; Kite, a Gilead company, Santa Monica, CA., Pasquini MC; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI.

Publikováno v: Blood [Blood] 2024 Jun 27; Vol. 143 (26), pp. 2722-2734.

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.

Autor: Juric D; Termeer Center for Targeted Therapies, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Barve M; Medical Oncology, Mary Crowley Cancer Research, Dallas, Texas, USA., Vaishampayan U; Internal Medicine/Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA., Roda D; Department of Medical Oncology, University Hospital, Valencia, Spain., Calvo A; Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain., Jañez NM; Department of Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain., Trigo J; Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Greystoke A; Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK., Harvey RD; Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA., Olszanski AJ; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA., Opyrchal M; Division of Oncology, Washington University School of Medicine in St Louis, St Louis, Missouri, USA., Spira A; Medical Oncology, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.; Medical Oncology, Virginia Cancer Specialists, US Oncology Research, NEXT Oncology Virginia, Leesburg, Virginia, USA., Thistlethwaite F; Medical Oncology, The Christie NHS Foundation Trust and University of Manchester, Manchester, UK., Jiménez B; Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain., Sappal JH; Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Kannan K; Oncology Therapeutic Area Unit, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Riley J; Gastroenterology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Li C; Quantitative Clinical Pharmacology, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Li C; Statistical and Quantitative Sciences, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Gregory RC; Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Miao H; Clinical Development, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA., Wang S; Takeda Oncology Clinical Science, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts, USA.

Publikováno v: Cancer medicine [Cancer Med] 2024 Mar; Vol. 13 (5).

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.

Autor: Oluwole OO; Vanderbilt University Medical Cancer Center, Nashville, TN, USA. olalekan.oluwole@vumc.org., Forcade E; Service d'Hématologie Clinique et Thérapie Cellulaire, Centre Hospitalier Universitaire de Bordeaux, F-33000, Bordeaux, France., Muñoz J; Banner MD Anderson Cancer Center, Gilbert, AZ, USA., de Guibert S; Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France., Vose JM; University of Nebraska Medical Center, Omaha, NE, USA., Bartlett NL; Washington University School of Medicine and Siteman Cancer Center, St Louis, MO, USA., Lin Y; Mayo Clinic, Rochester, MN, USA., Deol A; Karmanos Cancer Center, Wayne State University, Detroit, MI, USA., McSweeney P; Colorado Blood Cancer Institute, Denver, CO, USA., Goy AH; John Theurer Cancer Center, Hackensack, NJ, USA., Kersten MJ; Amsterdam UMC, Location University of Amsterdam, Cancer Center Amsterdam, Amsterdam (on behalf of HOVON/LLPC), The Netherlands., Jacobson CA; Dana-Farber Cancer Institute, Boston, MA, USA., Farooq U; University of Iowa, Iowa City, IA, USA., Minnema MC; University Medical Center Utrecht (on behalf of HOVON/LLPC), Utrecht, The Netherlands., Thieblemont C; Paris University, Assistance publique-Hôpitaux de Paris, Hemato-oncology, F-75010, Paris, France., Timmerman JM; University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, USA., Stiff P; Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA., Avivi I; Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Tzachanis D; University of California San Diego, La Jolla, CA, USA., Zheng Y; Kite, a Gilead Company, Santa Monica, CA, USA., Vardhanabhuti S; Kite, a Gilead Company, Santa Monica, CA, USA., Nater J; Kite, a Gilead Company, Santa Monica, CA, USA., Shen RR; Kite, a Gilead Company, Santa Monica, CA, USA., Miao H; Kite, a Gilead Company, Santa Monica, CA, USA., Kim JJ; Kite, a Gilead Company, Santa Monica, CA, USA., van Meerten T; University Medical Center Groningen, Groningen (on behalf of HOVON/LLPC), The Netherlands.

Publikováno v: Bone marrow transplantation [Bone Marrow Transplant] 2024 Mar; Vol. 59 (3), pp. 366-372. Date of Electronic Publication: 2024 Jan 04.